Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5152W HIGH $3.70
Volume
51.42 K
Value Traded
85.45 K
Short % Float
0.22%
Days to Cover
1.0
-23.95%Week
-32.22%1 Month
-47.22%3 Month
-68.16%6 Month
-83.45%5 Year
-83.45%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
23.23 M
EPS (TTM)
-0.98
P/E Ratio
-
Ent. Value
85.38 M
Total Shares
42.21 M
Float Shares
12.35 M
Insiders
61.40%
Institutions
1.33%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BDMD Catalyst Timeline
Dated clinical, regulatory and corporate events for Baird Medical Investment Holdings Ltd
Catalyst Timeline
Dated clinical, regulatory & corporate events for Baird Medical Investment Holdings Ltd
2Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How BDMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Baird Medical Investment Holdings Ltd is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every BDMD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BDMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BDMD for Q2 2026. | ||||
BDMD Institutional Ownership Trends
BDMD Short Interest
Shares sold short, counted twice a month.
0.22%
Short % of Float
of tradable shares sold short
26.9K
Shares Sold Short
+5.6% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
84.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BDMD ranks across every disease it competes in
Competitive Position is a premium feature
See how BDMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBDMD News
BDMD▼ -2.8%today
Baird Medical Announces Regulatory Milestones in Vietnam and Egypt, Expanding International Reach of Microwave Ablation Technology
Baird Medical has announced new medical device registrations in Vietnam and preliminary regulatory approval in Egypt for its microwave ablation technology. These milestones are part of the company's strategy to expand its international presence and address a larger patient population. The company also plans to strengthen its commercial activities in the U.S. after receiving FDA clearance.
Read more →BDMDBaird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026
Baird Medical reported significant advancements in Q3 2026, including international market expansion and the introduction of irreversible electroporation technology through a strategic partnership. The company emphasized its commitment to physician training and engagement at global conferences. Baird Medical aims to enhance its technology portfolio and broaden its reach to more physicians and patients worldwide.
Read more →BDMDBaird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Baird Medical will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. The company focuses on minimally invasive treatment solutions and has received FDA clearance for its microwave ablation system. Management will also hold one-on-one meetings with institutional investors during the event.
Read more →BDMDBaird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026
Baird Medical Investment Holdings Ltd. reported a 25% revenue growth for the first half of 2026, reaching approximately $9.9 million. The company achieved a positive net income of $14,000, a significant turnaround from a loss of $11.4 million in the same period last year. This growth is attributed to increased sales outside of China, particularly in the U.S. and Hong Kong, along with reduced operating expenses.
Read more →BDMDBaird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally
Baird Medical and Alpmed have formed a strategic partnership to enhance the global development and commercialization of irreversible electroporation (IRE) technology. The collaboration aims to leverage Baird's regulatory expertise and Alpmed's innovation in IRE to create advanced ablation solutions. They plan to submit a 510(k) application to the FDA by the end of 2026 for a device targeting soft tissue tumors.
Read more →BDMD▲ +7.5%on this news
Baird Medical Announces First Microwave Ablation Procedures Using Its Technology in Vietnam and Argentina
Baird Medical has successfully completed its first microwave ablation procedures in Vietnam and Argentina, marking a significant step in its global expansion strategy. The procedures were performed by experienced medical professionals, showcasing the effectiveness of the company's minimally invasive technology. This development highlights Baird Medical's commitment to providing innovative treatment options worldwide.
Read more →BDMDBaird Medical Establishes Global Headquarters in New York City, Reinforcing Commitment to U.S. Commercial Expansion
Baird Medical has announced the relocation of its global headquarters to New York City to enhance its U.S. operations and support its growth strategy. This move follows the appointment of Mark Saxton as CEO of the U.S. subsidiary, aiming to strengthen the company's market presence. The headquarters will serve as a central hub for corporate leadership and strategic initiatives, facilitating better access to healthcare investors.
Read more →BDMD▲ +8.6%on this news
Baird Medical Expands Global Reach with Regulatory Clearance in Argentina
Baird Medical has received regulatory clearance for its Microwave Ablation systems in Argentina, marking a significant step in its international expansion efforts. This approval complements existing certifications in the U.S. and several Asian countries. The company is also pursuing additional registrations in various key markets, aiming to meet the growing global demand for minimally invasive therapies.
Read more →BDMDBAIRD MEDICAL INVESTMENT HOLDINGS LIMITED INDEX TO FINANCIAL STATEMENTS Page Baird Medical Investment Holdings Limited Unaudited Interim Condensed Consolidated Balance Sheets as of
Baird Medical Investment Holdings Limited released its unaudited interim financial statements for the six months ending June 30, 2025. Financial results indicate a substantial decline, with a reported net loss of approximately $11.36 million, contrasting with a profit of $4.33 million in the previous year. The total assets decreased slightly from about $77.96 million at the end of December 2024 to approximately $76.99 million by June 30, 2025. Major increases in operating expenses were noted, particularly in general administration and research and development.
Read more →BDMDBaird Medical to Participate in the American Thyroid Association (ATA) Annual Meeting
Baird Medical will participate in the American Thyroid Association Annual Meeting from October 30 to November 3, 2024, in Chicago. The company will showcase its microwave ablation technology at Booth 100 and host a presentation on advancements in thyroid treatment. This participation emphasizes Baird Medical's expansion into the U.S. market following FDA clearance for its devices.
Read more →BDMD▼ -12.9%on this newsshared move
Baird Medical Announces Preliminary Financial Results for the Six Months Ended June 30, 2024
Baird Medical Investment Holdings Ltd. reported preliminary financial results for the first half of 2024, showing a 13.8% increase in revenues and an 85.8% rise in net income. The company is optimistic about its expansion into the U.S. market following recent FDA clearances for its microwave ablation technology. This technology is seen as a promising alternative to traditional thyroidectomy for patients with benign thyroid tumors.
Read more →BDMD▼ -6.9%on this news· ran to -19% by day 3shared move
Baird Medical Lists in the U.S. on the Nasdaq Exchange
Baird Medical Investment Holdings Ltd. has successfully listed on the Nasdaq under the ticker BDMD, marking a significant milestone as it transitions to a public company. The company, known for its microwave ablation technology, aims to address unmet needs in the U.S. thyroid care market following recent FDA clearances. Co-Founder Wenyuan Wu celebrated the occasion by ringing the Opening Bell.
Read more →BDMDBaird Medical to Participate in Roth's 3rd Annual Healthcare Opportunities Conference
Baird Medical Investment Holdings Ltd. will participate in Roth's 3rd Annual Healthcare Opportunities Conference on October 9, 2024. The company, which specializes in microwave ablation technology, has recently expanded into the U.S. market after receiving FDA 510(k) clearances. Their technology presents a viable alternative to thyroidectomy for patients with benign thyroid tumors.
Read more →BDMDBaird Medical and ExcelFin Acquisition Corp Complete Business Combination
Baird Medical and ExcelFin Acquisition Corp have successfully completed their business combination, resulting in the formation of Baird Medical Investment Holdings Limited, which will start trading on Nasdaq under the ticker BDMD. The decision to merge received overwhelming support, with 99.9% of votes in favor during a special stockholder meeting. Following this acquisition, Baird Medical aims to expand its presence in the U.S. market, having recently obtained FDA clearance for its microwave ablation devices used in treating tumors. However, potential risks related to market expansion and recognition of expected benefits pose challenges.
Read more →About Baird Medical Investment Holdings Ltd
BIOPHARMAWATCH ELITE PLUS
Trade the next BDMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime